ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody Jun 18, 2008
In addition, ThromboGenics and BioInvent could potentially receive up to EUR450 million over the term of the collaboration based on the successful completion of a series of development and commercial milestones for multiple indications, as well as double digit royalties on potential product sales, including any backup antibodies based on inhibition of PlGF. ThromboGenics, which discovered TB-403, will receive 60% and BioInvent 40% of the revenue from the deal ... Professor Dsir Collen, CEO... (PR Newswire)
Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO Jun 2, 2008
Pharmacodynamic analyses demonstrated statistically significant changes at the MTD in plasma markers including VEGF-A, PlGF, and soluble VEGFR2, similar to the effects of other anti-angiogenic agents, and consistent with the anti-VEGFR activity of XL184. In addition, decreases in soluble MET were measured in 4 of 7 patients at the MTD who were analyzed for this endpoint. (PR Newswire)
Extra Drug Improves Rectal Cancer Treatment Apr 17, 2008
Avastin alone, or in combination with other treatments, increased levels of the factors VEGF, PlGF and SDF1 alpha, the researchers reported. Patients with higher levels of VEGF and PlGF after Avastin responded better to chemotherapy and radiation, Jain said. (MEDLINEplus)
ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer Jan 18, 2008
TB-403 is a monoclonal antibody that targets the angiogenic factor PlGF (placental growth factor). TB-403 has demonstrated strong inhibition of PlGF-associated angiogenesis and tumour growth in animal models, without affecting healthy tissues ... PlGF is a homologue of VEGF but, unlike other angiogenesis factors such as VEGF, it does not affect normal, physiological angiogenesis and is only involved in the angiogenesis process which takes place in the diseased tissue. (PR Newswire)
Antibody might help starve cancerous tumors Nov 5, 2007
The scientists found in studies of mice that an antibody against so-called placental growth factor (PlGF) blocks the growth and spread of many types of tumors ... "Since they work in essentially the same way, a combination treatment of these agents hasn't added much benefit in prolonging survival of cancer patients. We need complementary drug targets and we believe PlGF might be one. It needs to stand the test of time and rigorous clinical testing, but the findings in mice look promising." ...... (News-Medical.net)
ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell Nov 2, 2007
LEUVEN, Belgium and LUND, Sweden, November 2 /PRNewswire/ -- - Novel Anti-PlGF Antibody, TB-403, Being Developed by ThromboGenics and BioInvent for Cancer Expected to Enter the Clinic Later This Year ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, and co-development partner, BioInvent International (Nordic Exchange: BINV), announce today the publication of data in Cell(1) that highlight for the first time the therapeutic potential of anti-PlGF... (PR Newswire)
ThromboGenics and BioInvent Awarded Euro 2 Million EU Grant for ANGIOSTOP Anti-Angiogenesis Programme Dec 28, 2006
The new agents will be based on antibodies against Placental Growth Factor (PlGF) ... TB-403 has shown good inhibition of PlGF-associated angiogenesis and tumour growth in preclinical models ... The PlGF growth factor is secreted by tumours and is specifically expressed in cancer and chronic inflammatory conditions. (PR Newswire)
Blood Tests Could Warn of Pregnancy Complication Sep 8, 2006
They also had reduced levels of another substance called placental growth factor, or PlGF. Those who got preeclampsia at term and those who had gestational high blood pressure had a rise in the soluble endoglin and an increase in their sFlt1-to-PlGF ratio. "We haven't investigated this enough to say how often it occurs," Levine said. (MEDLINEplus)
Soluble Endoglin and Preeclampsia Sep 7, 2006
Background Alterations in circulating soluble fms-like tyrosine kinase 1 (sFlt1), an antiangiogenic protein, and placental growth factor (PlGF), a proangiogenic protein, appear to be involved in the pathogenesis of preeclampsia ... An increased level of soluble endoglin was usually accompanied by an increased ratio of sFlt1:PlGF. The risk of preeclampsia was greatest among women in the highest quartile of the control distributions for both biomarkers but not for either biomarker alone ...... (New England Journal of Medicine)
Molecules in blood foretell development of preeclampsia Sep 7, 2006
The increase in sFlt1 was accompanied by reduced levels of a substance, placental growth factor (PlGF). Both women with term preeclampsia and women with gestational hypertension had a simultaneous rise in soluble endoglin, and an increase in the ratio of sFlt1 to PlGF (high levels of sFlt1 and low levels of PlGF.) ... "Both soluble endoglin and the altered sFlt1/PlGF ratio appear to contribute to the development of preeclampsia, Dr. Levine said. "Severe disease usually occurs in women with high... (EurekAlert!)
The Preeclampsia Mystery Jul 19, 2006
Karumanchi also tested the women for two proteins that supply their blood vessels with much of their nourishment: VEGF and PlGF. He found that those with preeclampsia had between sixty and eighty-five per cent less of the proteins floating freely in their blood than those without the disease. Karumanchi knew that other researchers were likely to be skeptical of a new theory of preeclampsia; he wanted to show not only that elevated levels of soluble FLT corresponded with decreases in VEGF and... (New Yorker)
Placental growth factor may help body repair heart attack damage Apr 14, 2006
Bethesda, MD Heart attack patients produce higher levels of a natural substance in the body that plays a role in the growth of new blood vessels and this over-expression of placental growth factor (PlGF) may help reduce damage to the heart muscle, according to a new study in the April 18, 2006, issue of the Journal of the American College of Cardiology. "Because the degree of PlGF production released from the heart after a heart attack correlated with the improvement of cardiac function, we... (EurekAlert!)
